Humana faces significant earnings headwinds due to CMS reforms, star rating downgrades, and potential Medicaid clawbacks.

Humana’s stock performance and market strategies continue to be closely monitored by investors and analysts, with particular attention to how the company navigates industry challenges.

UnitedHealth's dip offers long-term value, backed by strong fundamentals, rising dividends, and growth potential. Learn why ...

Raymond (NSE:RYMD) James has upgraded Humana’s stock rating from Market Perform to Outperform, setting a new price target of $315, citing the company’s strong performance and favorable drug mix.

While robust first-quarter earnings and operational performance were reported ... Unlock comprehensive insights into our analysis of Humana stock in this financial health report.

Humana Inc. closed 39.15% below its 52-week high of $406.46, which the company reached on July 18th. The stock demonstrated a mixed performance when compared to some of its competitors Monday ...

The performance and reduced forecast led to a ... The warning about healthcare costs dragged other insurer stocks, with Humana (HUM), CVS Health (CVS), and Elevance Health (ELV) also among the ...

JPMorgan Chase & Co. dropped their price target on Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 18th. Robert W. Baird ...

Shares of Humana Inc. HUM advanced 1.33% to $252.86 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 3.26% to 5,844.19 ...

Shares of Humana Inc. HUM shed 1.51% to $249.53 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.07% to 5,659.91 and Dow ...